Replies to post #174750 on Biotech Values

[jq1234]

LLY Dulaglutide: Non-inferior margin is 0.4%. NVO is up 5% today at all time high, probably relieved it was non-inferior, not superior to Victoza. My guess is numerical worse than Victoza based on some interviews I read.